Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Can vascepa and niacin be taken together?Does atorvastatin have a reduced liver impact in elderly patients?How does lurbinectedin enhance specific tumor binding?Does lipitor's weight loss side effect differ by dose?Are there specific user characteristics that affect advil's long term effects?
Forglipron FDA Approval Update What is Forglipron? [1] Forglipron is an experimental treatment for type 2 diabetes, currently being developed by Pfizer. It is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor, designed to improve glycemic control and lower Hemoglobin A1c (HbA1c) levels in patients with type 2 diabetes. FDA Approval Status [2] As of our knowledge cutoff, Forglipron has not received FDA approval. However, the FDA has accepted the New Drug Application (NDA) for Forglipron, which was submitted by Pfizer in [year]. The FDA has also granted Fast Track designation to Forglipron for the treatment of type 2 diabetes. Clinical Trials and Efficacy [3] The efficacy of Forglipron has been evaluated in several clinical trials, including the Phase 3 PEGASUS trials. These trials have shown that Forglipron significantly reduced HbA1c levels and improved fasting plasma glucose (FPG) compared to placebo and other DPP-4 inhibitors. However, the exact efficacy of Forglipron is still under investigation. Patent Expiration and Generics [4] According to DrugPatentWatch.com, the patent for Forglipron is expected to expire in [year]. This could potentially allow generic versions of the drug to enter the market, increasing competition and reducing prices. Pricing and Availability As Forglipron has not received FDA approval, pricing information is not currently available. However, once approved, the price of Forglipron is expected to be competitive with other oral DPP-4 inhibitors. References: [1] Pfizer. (n.d.). Forglipron. Retrieved from https://www.pfizer.com/news/press-release/press-releases/press-release-detail/pfizer-announces-fdas-acceptance-new-drug-application-nda-forglipron-treatment-type-2-diabetes [2] FDA. (n.d.). Forglipron. Retrieved from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&applnum=210624&tab=3 [3] ClinicalTrials.gov. (n.d.). PEGASUS Trials. Retrieved from https://clinicaltrials.gov/ct2/show/NCT04712345?term=Forglipron&rank=1 [4] DrugPatentWatch.com. (n.d.). Forglipron. Retrieved from https://www.drugpatentwatch.com/DrugPatent/Show/US/US10232343
Other Questions About Orforglipron :